Publication: The International Finance Corporation’s Investments in the Pharmaceutical and Life Sciences Sector: Findings from Clustered Project Performance Assessment Reports
Loading...
Published
2025-07-30
ISSN
Date
2025-07-30
Author(s)
Editor(s)
Abstract
This clustered Project Performance Assessment Report (PPAR) chapeau report synthesizes evaluation findings from six International Finance Corporation (IFC) investment projects in the pharmaceutical and life sciences sector, specifically targeting generic prescription drugs and consumer health products across five countries in three regions. The projects were selected for PPAR through purposeful sampling in consultation with IFC’s Global Health team and regional industry departments. These projects were committed during FY 2017–18 and selected based in the achievement of early operating maturity. The clustered PPAR chapeau report addresses the following topics: (i) The efficacy of IFC’s investments in improving the accessibility, quality, and affordability of critical pharmaceuticals and life sciences products. (ii) Management of environmental and social (E&S) risks in these projects and their effect on environmental and social sustainability. (iii) Key internal and external factors that enabled or constrained IFC’s effectiveness in the projects. (iv) IFC’s additionality (that is, the benefit or value addition that IFC brings that a client would not otherwise have; additionality can be financial or nonfinancial) in projects beyond financing (for example, knowledge transfer, advisory services, World Bank Group collaboration, and E&S sustainability). (v) Lessons learned and their implications, which can be applied across the pharma value chain, particularly in developing markets, to resolve supply-side constraints.
Link to Data Set
Citation
“World Bank. 2025. The International Finance Corporation’s Investments in the Pharmaceutical and Life Sciences Sector: Findings from Clustered Project Performance Assessment Reports. © World Bank. http://hdl.handle.net/10986/43525 License: CC BY-NC 3.0 IGO.”
Digital Object Identifier
Associated URLs
Associated content
Other publications in this report series
Journal
Journal Volume
Journal Issue
Collections
Related items
Showing items related by metadata.
Publication Final Report with Recommendations for Reforming Bulgaria’s Pharmaceutical Sector(Washington, DC, 2015-05)This report presents a review of current issues in the pharmaceutical sector in Bulgaria, examining drug policy, regulation, pricing, formulary selection, distribution, expenditure, and to the extent possible, patterns of use in Bulgaria. Its recommendations are intended to serve as options for reform, by articulating short and long term strategies for managing pharmaceutical expenditure, improving system sustainability, and driving value for money in Bulgaria, thereby improving efficiency, equity, affordability and ultimately, access to prescription medicines. Although small, the Bulgarian pharmaceutical market is showing strong growth. Medicines comprise not only a disproportionate share of health care expenditure (38 percent of total health expenditure, compared with an EU average of around 25 percent), the burden of out of pocket (OOP) costs is also excessive, possibly as high as 81 percent of total pharmaceutical expenditure. Of perhaps greatest concern is that rapid expenditure growth is taking place without obvious improvements in health outcomes, and at the expense of population equity. Bulgaria does not yet have an integrated national medicines policy, and the pharmaceutical sector is characterized by various highly prescriptive and at times, arguably inconsistent policy levers. While the regulatory framework has been largely brought into line with current EU standards, existing mechanisms for listing, pricing and subsidizing medicines are not ensuring adequate value for money for the National Health Insurance Fund (NHIF), and are contributing to inefficiencies in the health sector. Current pharmaceutical policy settings appear focused on limiting NHIF outlays rather than prioritizing access and affordability, and afford little financial protection to patients.Publication Financing, Pricing, and Utilization of Pharmaceuticals in China(Washington, DC, 2010)This paper examines the financing, pricing, and utilization of pharmaceuticals in China the pharmaceutical system as it has evolved, and some changes that would improve it in the context of the national health reform process. The present paper builds upon earlier critical reviews and other papers published in the series china health policy notes. The paper is divided into four parts. The first section provides an overview of the Chinese pharmaceutical market: how the sector has grown; China's position in the global market; and size, composition, and trends in the domestic market. The second section examines the evolution and status of China's system of essential medicines, an area emphasized in the government's health reform plan announced in April 2009. It shows how the use of essential medicines has evolved over the two decades since the idea was formally adopted, and discusses why practice has fallen far short of the ideal. The third section looks at the issue that dominates today's debate: managing high pharmaceutical costs. It reviews the components of drug pricing, underscoring the argument that there is considerable scope for reducing prices. It looks at government attempts to control drug prices, and suggests why they did not succeed. Finally, the fourth section suggests measures to re-chart the path to reform.Publication The Pharmaceutical Sector of the Western Balkan Countries(World Bank, Washington, DC, 2008-02)There is a strong political will in the Western Balkan states to align the region's pharmaceutical legislation and practice with that of the European Union. Accordingly, recent policy changes were aimed at harmonization of policies with other European countries. Several national drug laws were updated or completely re-written in the last several years. More specifically, provisions were made for the simplification of drug registration requirements, licensing of professionals and businesses in the sector, implementation of ethics standards, price controls and reimbursement of drugs through national health insurance systems. Countries in the region have introduced various measures for cost containment, mostly through positive lists with various co-payment levels or expenditure caps for prescribing physicians. Some institutional buyers are using pooled procurement with open tenders to ensure lower prices. Nevertheless, there are still a number of challenges such as lack of enforcement of rules and standards, limited access to drugs for low income populations, inefficiencies in resource allocation and in the distribution chain, lack of control over physicians prescribing behavior and occasional conflicts between public health and industrial policy objectives. For the foreseeable future, there will be a need for further capacity building in the pharmaceutical sector, with a focus on increased oversight and higher professional standards, more efficient use of limited public resources, equity of access and rational use of medicines. Nevertheless, drug expenditure is set to grow in this region as it did in other countries in Eastern Europe, typically at a rate of about twice GDP growth, due to inevitable factors such as innovation, aging populations, increasing incomes and better access to healthcare.Publication Pharmaceutical Reform : A Guide to Improving Performance and Equity(World Bank, 2011-09-21)This publication, which is based on the unique methodology and tools developed for the World Bank Institute/Harvard School of Public Health Flagship Course on Health System Reform and Sustainable Financing, provides a powerful set of resources to help policy makers better navigate the complicated process of reforming pharmaceutical systems. Its problem solving approach complements technical resources and training curricula available on the discrete elements of a pharmaceutical sector. The application of the flagship approach to the pharmaceutical sector is both useful and timely. Ensuring the availability of medicines and the effective management of their procurement and distribution is central to the drive to achieve coverage and access to basic health care that is both universal and financially sustainable. Together, the methodology and case materials contained in this publication provide a rich resource from which policy makers in developing countries may draw to guide their efforts to meet these challenges. This book is designed to help participants gain a better understanding of all that goes on in the pharmaceutical sector. As noted above, it uses the flagship framework that we helped develop over the past decade. The essence of that approach is not to try to tell policy makers in detail what they should do. Rather it comprises a set of analytical tools that are combined into an overall, structured methodology for developing, adopting, and implementing reform proposals. The flagship framework also includes a comprehensive review of reform alternatives and a systematic review of their strengths and weaknesses in various situations. Throughout this book the authors have used the flagship framework to structure our analysis of pharmaceutical reform, continuously and explicitly applying its methods and concepts to the pharmaceutical sector. With a few minor exceptions, all the examples and all of the reform options come directly from pharmaceutical reform efforts around the world. The authors have also given specific attention to issues in pharmaceutical policy related to reproductive health.Publication A Practical Approach to Pharmaceutical Policy(World Bank, 2010)This book discusses the wide range of challenges faced by policy makers in the pharmaceutical sector, presents the current know-how in terms of policy measures, and provides specific examples of policy packages that can be used in defined circumstances, even if one assumes a certain degree of political resistance and capacity limits on the side of the implementing agency. This book focuses on developing countries and tries to address the issues faced by both low- and middle-income countries. The book does not cover the vaccines market and its respective policies because too many differences exist between the markets for vaccines and pharmaceuticals to cover both subsectors in one publication of this type. The book ends with an outlook on how things might evolve in the longer term. It assumes that some form of convergence will take place toward "models that work," thus reducing the fragmentation of policies and enhancing regulatory and economic efficiencies over time-one hopes to the benefit of all stakeholders in the sector and, in particular, those who, as patients, currently do not have reliable access to effective and safe medicines.
Users also downloaded
Showing related downloaded files
Publication The World Bank Group in Georgia, 2014-23(Washington, DC: World Bank, 2025-07-30)This Country Program Evaluation assesses the performance and effectiveness of the World Bank Group’s support to Georgia in achieving the country’s development objectives. In the decade leading up to the evaluation period, Georgia pursued economic reforms to attract critical investments for becoming a regional trade and transport hub. Ambitious economic reforms went hand in hand with efforts to improve human development and strengthening social protection systems. Growing geopolitical tensions and internal political polarization have challenged Georgia’s reform progress in recent years. The Bank Group’s strategy adapted well to Georgia’s development needs and was well coordinated with other development partners. It successfully employed a range of instruments to help increase competitiveness, growth, and job creation, and effectively contributed to improved infrastructure and increased trade by using programmatic and innovative approaches. The Bank Group’s regular investments in analytical work and the switch to results-based programmatic support helped improve the efficiency and effectiveness of education and health care systems. The IEG offers the following lessons based on the evidence and analysis in the Country Program Evaluation: (i) Prioritizing Bank Group support around the move towards deeper regional integration was an effective anchor for key economic reforms for economic convergence. (ii) Pursuing a selective and adaptive approach in a country with high implementation capacity and institutions, strong coordination among development partners, and access to a wide range of external resources can allow the Bank Group to exercise significant influence in areas of comparative advantage and global expertise. (iii) A stronger focus on outcome-based programmatic approaches helped to build local capacity and crowd-in partner financing.Publication The World Bank Group in Tanzania, Fiscal Years 2012–22(Washington, DC: World Bank, 2025-07-22)This evaluation assesses the relevance and effectiveness of the World Bank Group's support to Tanzania between Fiscal Years 2012 and 2022. Over the past decade, Tanzania has experienced resilient growth, with an average annual per capita GDP increase of 2.2%. However, poverty remains widespread and slow to decline, underscoring the need for more inclusive growth. The report examines the Bank Group's strategic and operational approaches during this period, which were aligned with Tanzania's development priorities and focused on industrialization, human development, and public sector reforms. The evaluation includes thematic chapters on the Bank Group's support for private sector-led growth and spatial transformation, as well as lessons to inform future support to the country.Publication Evaluation Insight Note(Washington, DC: World Bank, 2025-07-30)Supporting countries in their fertility transitions can entail different entry points, such as improving access to reproductive health services, raising awareness and knowledge of family planning, promoting female education and life skills, expanding women’s economic opportunities, and addressing social and cultural norms. The World Bank’s strategies highlight the critical intersection among reproductive health, gender equality, and human capital formation over the past two decades. This Evaluation Insight Note (EIN) synthesizes existing evidence from evaluations and systematic reviews on effective strategies to support high-fertility transitions, drawing lessons to guide future initiatives.Publication FY 2025 China Country Opinion Survey Report(Washington, DC: World Bank, 2025-08-04)The Country Opinion Survey in China assists the World Bank Group (WBG) in better understanding how stakeholders in China perceive the WBG. It provides the WBG with systematic feedback from national and local governments, multilateral/bilateral agencies, media, academia, the private sector, and civil society in China on 1) their views regarding the general environment in China; 2) their overall attitudes toward the WBG in China; 3) overall impressions of the WBG’s effectiveness and results, knowledge work and activities, and communication and information sharing in China; and 4) their perceptions of the WBG’s future role in China.Publication Preparedness for Epidemics and Pandemics(Washington, DC: World Bank, 2025-06-18)This evaluation focuses on the preparedness of the World Bank Group, including the World Bank and the International Finance Corporation (IFC), to support epidemic- and pandemic-related health emergencies. A health emergency is defined as an extraordinary event that is determined to constitute a public health risk to other states through the international spread of disease and to potentially require a coordinated international response. While health emergencies can include natural disasters or humanitarian crises that impact the health of populations, the evaluation centers on the preparedness—including prevention, detection, and readiness—to act quickly in health emergencies whose origins or sources are related to infectious disease outbreaks and antimicrobial resistance. Globally, the increasing risk of outbreaks and epidemics that could escalate into pandemic health emergencies underscores the need for countries to be better prepared. A strong development and economic rationale exists for investing in preparedness to reduce the risk of outbreaks and epidemics. According to the Global Health Security Index—which measures 195 countries’ preparedness and capacity to respond to epidemics and pandemics—all countries are dangerously unprepared for epidemics and pandemics, with less developed countries being particularly vulnerable because of their weak systems. The evaluation’s purpose is to assess the Bank Group’s support for epidemic preparedness, which aims to help client countries prevent, detect, and ensure readiness for infectious disease outbreaks. This evaluation will provide insights into the effectiveness of past and ongoing preparedness efforts supported by the World Bank, specifically examining what works and why. These findings can inform scale-up to enhance efforts of the World Bank’s HEPPR Global Challenge Program. The evaluation will focus on the support of the World Bank and IFC. Given that the Multilateral Investment Guarantee Agency has a relatively small and predominantly new portfolio in this area, it will not be included in the evaluation.